CEOS see Quick ROI on Digital Transformation and AI Investments
KPMG-a business solutions, audit, tax, and advisory professional services firm-released its 2018 CEO Outlook. The report found that CEOs at large life sciences companies anticipate quickly recovering investments in digital transformation and artificial intelligence (AI), while those in the U.S. expect, or have accomplished, quicker returns than their global peers.
Among the U.S. CEOs surveyed this year, 25% said they have already achieved significant returns from AI investments and also digital transformation programs that have reshaped business functions such as product development, finance, IT, human resources, regulatory compliance, and marketing. Only 9% of global life sciences CEOs said they’ve already achieved a significant return on investment in AI and digital transformation programs.
Another 33% of CEOs surveyed-globally and in the U.S.-expect their investments in digital transformation to pay off within 12 months, the survey found.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
